Dr Yuan Ma | Nucleic acid drug | Best Researcher Award

RAP at Hong Kong Baptist University,China

Dr. Yuan Ma is a distinguished Research Assistant Professor at the Hong Kong Baptist University (HKBU) specializing in aptamer-based translational research and drug discovery. With over a decade of experience in nucleic acid chemistry and pharmaceutical sciences, Dr. Ma has made significant contributions to targeted cancer therapies and bone disease treatments. 📚🔬

Profile

orcid

scopus

🌟 Early Academic Pursuits

Dr. Yuan Ma’s academic journey is a testament to dedication and excellence in pharmaceutical sciences. Starting at Peking University, one of China’s premier institutions, he earned his Bachelor of Science in 2013, focusing on organic chemistry, pharmacology, and pharmaceutical analysis. He further pursued a Master of Science (2015) and a Doctor of Philosophy (2019) in the Stake Key Laboratory of Natural and Biomimetic Drugs. His PhD research, supervised by Prof. Zhenjun Yang, delved into the biological activity and mechanisms of novel nucleoside lipid delivery systems, solidifying his expertise in nucleic acid and organic chemistry. 🌱

🚀 Professional Endeavors

Dr. Ma’s professional trajectory has been marked by impactful roles across leading institutions. From 2019 to 2020, he served as an Associate Research Fellow at Mengchao Hepatobiliary Hospital, Fujian Medical University, focusing on nucleic acid-based therapies for primary liver cancer. Transitioning to Hong Kong Baptist University in 2020, he assumed roles as a Postdoctoral Research Fellow and later as a Research Assistant Professor, contributing significantly to aptamer-based translational research and drug discovery. His current position places him at the forefront of advancing translational medicine in bone and joint diseases. 💼

🔬 Contributions and Research Focus

Dr. Ma has carved a niche in aptamer-based therapies, emphasizing translational research and drug discovery. His research addresses critical challenges in cancer therapy, bone regeneration, and drug delivery systems. By pioneering aptamer-conjugated compounds, he has significantly advanced the efficacy and precision of therapeutic interventions, particularly for conditions like triple-negative breast cancer and osteogenesis imperfecta. His work in chemically modified aptamers has also enhanced protein-binding affinities, setting new standards in nucleic acid therapeutics. 🧪

🏅 Accolades and Recognition

With an H-index of 11, Dr. Ma’s scholarly impact is evident in his prolific publication record, comprising 33 high-impact articles in leading journals such as Molecular Therapy Nucleic Acids and Cancer Letters. His innovative research has garnered attention for its role in advancing both fundamental science and clinical applications. As a co-first and corresponding author, he continues to lead pivotal studies that shape the future of aptamer technologies. 🏆

🌏 Impact and Influence

Dr. Ma’s contributions extend beyond the laboratory. As an educator, he has mentored postgraduate students in cutting-edge projects, from PROTAC drugs for cancer treatment to single-cell transcriptomics. His dedication to teaching complex courses, including Herbal Pharmacology and Translational Medicine, reflects his commitment to nurturing the next generation of scientists. His collaborative ethos has fostered partnerships across disciplines, bridging gaps between pharmaceutical science and clinical practice. 🌐

📖 Legacy and Future Contributions